Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III

Publisher： Karger

E-ISSN： 1421-9751|116|4|292-301

ISSN： 0008-6312

Source： Cardiology, Vol.116, Iss.4, 2010-09, pp. : 292-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE)

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 4, 2015-04 ,pp. : 374-384

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Benefit and Approach of Ultrafiltration in Acute Heart Failure

By  

Cardiology, Vol. 96, Iss. 3-4, 2002-01 ,pp. : 144-154

Karger

Access to resources Recommend Favorite

Clinical Experience with Ivabradine in Acute Heart Failure

By  

Cardiology, Vol. 134, Iss. 3, 2016-04 ,pp. : 372-374

Karger

Access to resources Recommend Favorite

Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 11, 2015-11 ,pp. : 1114-1123

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 20, Iss. 1, 2018-01 ,pp. : 164-174

John Wiley & Sons Inc

Access to resources Recommend Favorite